These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 31377744)
21. B2M overexpression correlates with malignancy and immune signatures in human gliomas. Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560 [TBL] [Abstract][Full Text] [Related]
22. Single cell RNA sequencing reveals differentiation related genes with drawing implications in predicting prognosis and immunotherapy response in gliomas. Zhou Z; Wei J; Yang Z; Bao Y; Jiang W; Lu B; Wang W; Li L Sci Rep; 2022 Feb; 12(1):1872. PubMed ID: 35115572 [TBL] [Abstract][Full Text] [Related]
23. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Sloan KE; Stewart JK; Treloar AF; Matthews RT; Jay DG Cancer Res; 2005 Dec; 65(23):10930-7. PubMed ID: 16322240 [TBL] [Abstract][Full Text] [Related]
24. Novel roles of VAT1 expression in the immunosuppressive action of diffuse gliomas. Yang P; Wang K; Zhang C; Wang Z; Liu Q; Wang J; Jiang T; Shan X Cancer Immunol Immunother; 2021 Sep; 70(9):2589-2600. PubMed ID: 33576871 [TBL] [Abstract][Full Text] [Related]
25. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036 [TBL] [Abstract][Full Text] [Related]
26. Zhang J; Fu M; Zhang M; Zhang J; Du Z; Zhang H; Hua W; Mao Y Front Oncol; 2021; 11():665360. PubMed ID: 34178649 [No Abstract] [Full Text] [Related]
27. Tumor Purity as an Underlying Key Factor in Glioma. Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819 [No Abstract] [Full Text] [Related]
28. Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. Chandramohan V; Bryant JD; Piao H; Keir ST; Lipp ES; Lefaivre M; Perkinson K; Bigner DD; Gromeier M; McLendon RE Arch Pathol Lab Med; 2017 Dec; 141(12):1697-1704. PubMed ID: 28829151 [TBL] [Abstract][Full Text] [Related]
29. High expression of BTN3A1 is associated with clinical and immunological characteristics and predicts a poor prognosis in advanced human gliomas. Kone AS; Ghouzlani A; Qandouci A; Issam Salah NEI; Bakoukou Y; Lakhdar A; Karkouri M; Badou A Front Immunol; 2024; 15():1397486. PubMed ID: 38863709 [TBL] [Abstract][Full Text] [Related]
30. ARL3 is downregulated and acts as a prognostic biomarker in glioma. Wang Y; Zhao W; Liu X; Guan G; Zhuang M J Transl Med; 2019 Jun; 17(1):210. PubMed ID: 31234870 [TBL] [Abstract][Full Text] [Related]
31. A risk signature of four aging-related genes has clinical prognostic value and is associated with a tumor immune microenvironment in glioma. Luo H; Tao C; Long X; Huang K; Zhu X Aging (Albany NY); 2021 Jun; 13(12):16198-16218. PubMed ID: 34114970 [TBL] [Abstract][Full Text] [Related]
32. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489 [TBL] [Abstract][Full Text] [Related]
33. Clinical and molecular immune characterization of ERBB2 in glioma. Mei J; Wang T; Xu R; Chen D; Zhang Y Int Immunopharmacol; 2021 May; 94():107499. PubMed ID: 33640859 [TBL] [Abstract][Full Text] [Related]
34. Immune and Clinical Features of Zhang Q; Zhong H; Fan Y; Liu Q; Song J; Yao S; Cao F Front Bioeng Biotechnol; 2020; 8():592. PubMed ID: 32695752 [TBL] [Abstract][Full Text] [Related]
35. CTSB is a negative prognostic biomarker and therapeutic target associated with immune cells infiltration and immunosuppression in gliomas. Ma K; Chen X; Liu W; Chen S; Yang C; Yang J Sci Rep; 2022 Mar; 12(1):4295. PubMed ID: 35277559 [TBL] [Abstract][Full Text] [Related]
36. Increased Soluble CD226 in Sera of Patients with Cutaneous T-Cell Lymphoma Mediates Cytotoxic Activity against Tumor Cells via CD155. Takahashi N; Sugaya M; Suga H; Oka T; Kawaguchi M; Miyagaki T; Fujita H; Inozume T; Sato S J Invest Dermatol; 2017 Aug; 137(8):1766-1773. PubMed ID: 28395975 [TBL] [Abstract][Full Text] [Related]
37. A gene expression-based study on immune cell subtypes and glioma prognosis. Zhong QY; Fan EX; Feng GY; Chen QY; Gou XX; Yue GJ; Zhang GH BMC Cancer; 2019 Nov; 19(1):1116. PubMed ID: 31729963 [TBL] [Abstract][Full Text] [Related]
38. Progression from low- to high-grade in a glioblastoma model reveals the pivotal role of immunoediting. Appolloni I; Alessandrini F; Ceresa D; Marubbi D; Gambini E; Reverberi D; Loiacono F; Malatesta P Cancer Lett; 2019 Feb; 442():213-221. PubMed ID: 30312732 [TBL] [Abstract][Full Text] [Related]
39. Mathematical modeling of PDGF-driven glioma reveals the dynamics of immune cells infiltrating into tumors. Niu B; Zeng X; Phan TA; Szulzewsky F; Holte S; Holland EC; Tian JP Neoplasia; 2020 Sep; 22(9):323-332. PubMed ID: 32585427 [TBL] [Abstract][Full Text] [Related]
40. CD155, an onco-immunologic molecule in human tumors. Gao J; Zheng Q; Xin N; Wang W; Zhao C Cancer Sci; 2017 Oct; 108(10):1934-1938. PubMed ID: 28730595 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]